Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Delta-9-Tetrahydrocannabinol Clear all

Conditions: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Pain, Abuse, Drug, Intoxication; Cannabinoids
Interventions: Cannabis, Dronabinol, Smoked Placebo, Oral Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Irritable Bowel Syndrome
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions: Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1; Drug
Lead sponsor: Leslie Lundahl; Other
Eligibility: 18 Years to 60 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Pain, Widespread
Interventions: Delta-9-Tetrahydrocannabinol, Cannabidiol, Placebos; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 50 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Spasticity With Multiple Sclerosis
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more

Conditions: Endometriosis, CBD, Pelvic Pain
Interventions: Cannabidiol (CBD) Extract, Norethindrone Acetate, Placebo; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Cannabis Intoxication
Interventions: Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cannabis Use Disorder
Interventions: THC, Alprazolam, Placebo oral capsule, CBD; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psychedelic Effects in Healthy Volunteers
Interventions: Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions: IGC-AD1-Active, IGC-AD1-Placebo; Drug
Lead sponsor: IGC Pharma, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more

Conditions: Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions: THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Marijuana Dependence
Interventions: Nicotine, Cannabis, PAX Loose Leaf Vaporizer; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatic Impairment
Interventions: Sativex; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Anaheim, California • Miami, Florida

Conditions: Cannabis Use
Interventions: Packaging imagery, No Imagery (Control); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pain, Appetite Loss, Abuse, Drug
Interventions: Placebo, Low CBG, High CBG, Low THC, High THC; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma
Interventions: Cannabis, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Cannabis
Interventions: Inhaled THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Cannabis, Drug Effects, Driving Performance
Interventions: 5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage, Placebo Capsule + Placebo Beverage; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 21 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: West Bend, Wisconsin

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Post Traumatic Stress Disorder, Cannabis Use, Suicide, Veterans, Marijuana
Interventions: Tetrahydrocannabinol, Cannabidiol, Placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 19 Years to 69 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Total Knee Arthroplasty, Opioid Use
Interventions: Dronabinol 5mg Cap, Placebo oral tablet; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 70 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions: Dronabinol, dextrose; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Abuse, Drug, Pain
Interventions: Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Age-dependent Effects of Smoked and Oral Delta-9-THC

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Cannabidiol and Management of Endometriosis Pain

Pregnenolone as a Treatment for Cannabis Intoxication

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Investigation of Psychedelic Effects in Psychoactive Substances

Clinical Trial on Agitation in Alzheimer's Dementia

Cannabis' Impact on Alcohol Consumption

Vaping THC From Electronic Cigarettes

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Cannabis Edibles Packaging Imagery Experiment

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

Warrior CARE: Cannabis Behavioral Health

Dronabinol in Total Knee Arthroplasty (TKA)

Individual Differences in Drug Response

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy